Haisco and AirNexis Forge Major Licensing Deal for Groundbreaking Drug HSK39004 Haisco Pharmaceutical has partnered with AirNexis for the global development of innovative COPD drug HSK39004 in a deal exceeding $1 billion, marking China's significant entry into the respiratory drug market.

Haisco and AirNexis Forge Major Licensing Deal for Groundbreaking Drug HSK39004 #None #HSK39004 #Haisco #AirNexis